Argireline vs SNAP-8

Argireline is a trade name. On an ingredient list the molecule appears as acetyl hexapeptide-8, and on older packaging as the retired acetyl hexapeptide-3. Both names sit on one PubChem compound record, with acetyl hexapeptide-8 tagged as the INCI name. The chain is six amino acids, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. A serum can contain it without the word Argireline appearing anywhere on the box.

SNAP-8 is a trade name too. The INCI name is acetyl octapeptide-3, and PubChem carries SNAP-8 on that same record as a trade mark rather than a chemical name. The chain is eight amino acids, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2. Same rule applies: the trade name is what the marketing uses, and the INCI name is the only thing on the label that tells you the ingredient is in there.

Up to 30 percent less wrinkle depth over 30 days. That figure traces to a single paper: Blanes-Mira and colleagues, International Journal of Cosmetic Science, 2002, testing an oil in water emulsion carrying the peptide at 10 percent on healthy women volunteers. It went through peer review. It was also written by the team that created the molecule.

A maximum near 62 percent, with a mean nearer 35 percent. This one never went through peer review at all. The 2020 review in Frontiers in Chemistry reports both figures and says exactly where they came from: the data available on the manufacturer's website. The mean is the number vendor copy tends to leave out.

Thin, but it exists. Wang and colleagues ran a randomized placebo-controlled trial in 60 Chinese subjects, 3 to 1 active against placebo, over four weeks, published in the American Journal of Clinical Dermatology in 2013; total anti-wrinkle efficacy came out at 48.9 percent against 0 percent for placebo. A team at the NIH neurological institute ran a double-blind placebo-controlled pilot in 24 patients already on botulinum toxin therapy, published in the European Journal of Neurology the same year.

Effectively none isolating the molecule. A PubMed search for acetyl octapeptide-3 returns two clinical papers. Both test microneedle patches carrying several actives at once, one alongside hyaluronic acid and two other ingredients, the other alongside four. Both carry authors from the company that makes the patch. Neither measures what the peptide does on its own, which is the question a shopper is actually asking.

Both are read as fragments of SNAP-25 competing for a place in the SNARE complex, the machinery a nerve ending uses to release acetylcholine. Argireline covers the N-terminal domain of that protein. The 2025 International Journal of Molecular Sciences review states that none of the in vivo application studies it surveyed confirmed the peptide inhibiting muscle contraction.

The same story with two extra residues. The 2020 Frontiers in Chemistry review describes SNAP-8 mimicking SNAP-25 as a competitive inhibitor, with its inhibition figures measured in a cell assay rather than on skin. That distinction matters, because a molecule can behave in a dish and still never reach the place it would need to reach.

There is a published answer, and it is uncomfortable. When the Expert Panel for Cosmetic Ingredient Safety reviewed industry-reported use data and published its assessment in the International Journal of Toxicology in 2025, it concluded that acetyl hexapeptide-8 amide is safe in cosmetics at concentrations up to 0.005 percent, and that the available data were not sufficient above that. The studies behind the famous figure ran at 10 percent.

No equivalent panel assessment has been published. Nothing in the peer-reviewed record tells you what concentration finished SNAP-8 products carry, and nothing tells you what that concentration does. The manufacturer figures arrived without the methodological detail that would let anyone check them, so SNAP-8 has the same concentration gap Argireline has, minus the published number that describes it.

There is a published harm signal. A 2021 case report in World Journal of Clinical Cases describes a woman who developed erythema, nodules, and abscesses a week after facial injections of argireline, with pus cultures positive for Mycobacterium abscessus and five months of antibiotics before she improved. One case is one case. It is still one more than the injectable route has efficacy data for.

No comparable case report turns up in PubMed, and no efficacy data for the route exists either. An absence of published cases is not a safety finding; it is what a smaller and newer gray market looks like in the literature. Both molecules were designed and sold as topical cosmetics, and gray-market vials sit outside the cosmetic safety review entirely.

A 2024 longitudinal analysis in JMIR Dermatology tracked United States search interest from 2013 to 2023 and found people searched overwhelmingly for the trade name first and the Botox in a bottle nickname second, with the two scientific names flat along the bottom. Interest was sparse before 2015, climbed from May 2021, and peaked in October 2022.

No equivalent analysis has been published for SNAP-8, but the lesson carries over. People shop by trade name, and the trade name is the part of a label that tells you nothing about how much of the ingredient is in the bottle. The INCI name is the part that does, and it is printed in the smallest type on the package.